Current research is focused on expanding the pipeline of antifungal agents through the development of novel drug classes and the optimization of existing ones. New strategies include the use of synergistic combinations, where two drugs are used together to enhance efficacy and reduce the likelihood of resistance. Additionally, scientists are exploring natural sources, such as essential oils and plant-derived compounds, for their potential as safer, broad-spectrum alternatives. As fungal pathogens continue to adapt, the ongoing development of innovative antifungal agents remains essential for modern medicine's ability to treat life-threatening infections.
The primary target for many antifungal drugs is the fungal cell membrane, specifically the molecule ergosterol. Ergosterol serves a similar function to cholesterol in human cells, maintaining membrane fluidity and integrity. Azoles, one of the most widely used classes of antifungals, work by inhibiting the enzyme 14-alpha-demethylase, which is essential for ergosterol synthesis. By depleting ergosterol and causing the accumulation of toxic precursors, azoles disrupt the fungal membrane. Another class, polyenes—such as Amphotericin B—act directly on the membrane by binding to ergosterol and forming pores, which causes vital cellular contents to leak out and leads to cell death. antifungal agent
Target the cell wall by inhibiting glucan synthesis; generally well-tolerated. Current research is focused on expanding the pipeline